Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

por Cassidy, J, Douillard, J-Y, Twelves, C, McKendrick, J J, Scheithauer, W, Bustová, I, Johnston, P G, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T S, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K K, Cowell, W, Garrison, L P
Publicado 2006